In 2026, Medicare and Medicaid in the US are navigating complex changes around coverage of weight loss services and medications. While blockbuster GLP-1 drugs like Ozempic and Wegovy show promise for weight loss, their coverage under federal health programs remains limited and evolving.

Key Figures and Dates at a Glance

  • Medicare weight loss drug coverage remains restricted; GLP-1 drugs only covered for diabetes, not obesity, as of 2026.
  • Medicare’s BALANCE model to start May 2026 (Medicaid) and January 2027 (Medicare Part D), offering discounted GLP-1 drugs at $50/month.
  • Short-term Medicare demonstration program for GLP-1 weight loss drugs runs July 2026 through December 2031.
  • About 69% of Medicare beneficiaries are overweight (35%) or obese (34%) as of 2024.
  • Medicare beneficiaries with type 2 diabetes (affecting 25% of enrollees) can access GLP-1 drugs for diabetes treatment.
  • Proposed 2026 rule to expand Medicare coverage for anti-obesity drugs was rejected in April 2025.
  • Medicaid states can opt into the BALANCE program starting May 2026.
  • Eli Lilly and Novo Nordisk GLP-1 drugs negotiated for discounted rates under BALANCE.
  • Estimated 3.4 million adults could have gained coverage under the rejected expansion proposal.
  • Monthly copay for weight loss drugs under the BALANCE model capped at $50 for eligible beneficiaries.
  • As of 2024, the average monthly cost for GLP-1 drugs like Wegovy without discounts ranges between $1,200 to $1,400.
  • The demonstration program plans to include about 500,000 Medicare beneficiaries who have obesity.

Overview: Medicare and Medicaid Weight Loss Services in 2026

Obesity remains a serious health problem in the US, impacting many Medicare beneficiaries. Data from 2024 shows that 69% of Medicare enrollees fall into overweight or obese categories—35% overweight and 34% obese. This places millions at elevated risk for chronic diseases such as diabetes, heart disease, and stroke.

Even though the need is high, Medicare still doesn't cover GLP-1 drugs when they're prescribed just for obesity. These medications, including Wegovy and Ozempic, are only covered for beneficiaries with diabetes or related chronic conditions. This restriction has been a point of contention, especially as these drugs have demonstrated effective weight loss in clinical trials.

Medicaid coverage varies widely by state. Some states have embraced recent CMS initiatives to broaden access.

The BALANCE model started in May 2026 for Medicaid and will begin in January 2027 for Medicare Part D. It offers discounted prices and more support for weight loss meds. States opting into BALANCE will provide beneficiaries with access to GLP-1 drugs at a capped copay of $50 per month—a steep discount compared to retail prices.

The Centers for Medicare and Medicaid Services (CMS) also approved a short-term Medicare demonstration program beginning July 2026 through December 2031. This program will provide temporary coverage for GLP-1 drugs for obesity for a select group of beneficiaries, aiming to collect data on outcomes and costs before any permanent policy changes.

Weight Loss Medication Options Under Medicare and Medicaid

GLP-1 receptor agonists, like Wegovy (semaglutide) and Ozempic, have become the most talked-about weight loss drugs in recent years. Their ability to suppress appetite and regulate blood sugar has led to an average weight loss of 15% or more in clinical trials. However, as of 2026, Medicare only covers these drugs when prescribed for type 2 diabetes treatment.

Medicare beneficiaries with type 2 diabetes—about 25% of all enrollees—can access GLP-1 drugs under their Part D prescription drug plans. But beneficiaries seeking these medications purely for weight management must currently pay out of pocket or rely on Medicaid coverage if available.

Medicaid policies are a patchwork. Some states cover anti-obesity medications broadly, others limit coverage to diabetes, and some exclude coverage altogether. The BALANCE program represents the first federal effort to standardize access across states that choose to participate. By negotiating discounted prices with leading drugmakers Eli Lilly and Novo Nordisk, CMS aims to reduce costs for beneficiaries and the government.

Without the BALANCE program, many seniors and low-income people face monthly costs over $1,200 for GLP-1 drugs, which is just too expensive. Under BALANCE, the monthly copay is capped at $50, potentially saving beneficiaries over $1,000 per month. That could significantly increase adherence and health outcomes.

State and Regional Differences in Coverage

Medicaid coverage for weight loss drugs varies by state, reflecting different budget priorities and health policies. As of mid-2026, around 20 states opted into the BALANCE program. These states include California, New York, Illinois, and Pennsylvania—home to large Medicaid populations.

States not participating in BALANCE generally maintain more restrictive policies. For example, Texas and Florida limit Medicaid coverage of GLP-1 drugs to diabetes only, while some smaller states don't cover them at all for weight loss.

The disparity means that a Medicaid beneficiary in California could pay $50 per month for Wegovy under BALANCE, while a similar beneficiary in Texas might pay over $1,200 out of pocket or not have access at all.

Medicare coverage is consistent nationally but limited, as it doesn't cover obesity treatment with GLP-1s outside of diabetes. The upcoming Medicare Part D expansion through the BALANCE model starting January 2027 will affect all Medicare beneficiaries nationwide, but only if Congress supports ongoing funding.

Forecast and Future Developments

The landscape for weight loss services under Medicare and Medicaid is poised for change, but slowly. The rejection of the 2026 proposed rule to expand anti-obesity drug coverage by Medicare in April 2025 delayed broad access for millions. That proposal could have expanded coverage to an estimated 3.4 million adults, including many without diabetes.

Still, the BALANCE program and the Medicare demonstration project signal a cautious shift toward wider access. The Medicare demonstration program, running from July 2026 to December 2031, plans to enroll around 500,000 beneficiaries. Data from this program will be critical in assessing the impact on health outcomes and costs, guiding future coverage decisions.

Industry negotiations have brought monthly prices down under BALANCE to $50 copays, a dramatic cut from list prices exceeding $1,200. This may encourage more states to join the program and push Medicare toward permanent coverage expansions.

Experts predict that if the demonstration shows positive health benefits and cost savings, Medicare could formally expand coverage of GLP-1 and other anti-obesity drugs by 2030. Medicaid expansion will likely continue on a state-by-state basis, with more states joining BALANCE or adopting similar programs.

Meanwhile, the demand for weight loss services continues to grow. With nearly 70% of Medicare beneficiaries overweight or obese, the need for affordable, effective treatments remains urgent. Free support services such as counseling and nutrition education are offered through some Medicaid programs and the BALANCE initiative, aiming to complement medication use.

2026 marks a transitional year. Coverage for weight loss drugs under Medicare is still limited but evolving, while Medicaid coverage depends heavily on state participation. The BALANCE program and demonstration projects offer a glimpse of more accessible options on the horizon.

Medicare beneficiaries in 2026 face limited access to weight loss medications, with coverage mainly available for diabetes treatment. Medicaid coverage varies widely by state, though the BALANCE program offers a new path toward affordable access starting May 2026. Demonstration programs running through 2031 will test the impact of these drugs on health outcomes and costs, potentially paving the way for broader coverage in the coming years.